The world's first wiki where authorship really matters (Nature Genetics, 2008). Due credit and reputation for authors. Imagine a global collaborative knowledge base for original thoughts. Search thousands of articles and collaborate with scientists around the globe.

wikigene or wiki gene protein drug chemical gene disease author authorship tracking collaborative publishing evolutionary knowledge reputation system wiki2.0 global collaboration genes proteins drugs chemicals diseases compound
Hoffmann, R. A wiki for the life sciences where authorship matters. Nature Genetics (2008)
MeSH Review

Medical Oncology

Welcome! If you are familiar with the subject of this article, you can contribute to this open access knowledge base by deleting incorrect information, restructuring or completely rewriting any text. Read more.

Disease relevance of Medical Oncology


High impact information on Medical Oncology

  • Of 50 well-characterized SCLC lines recently described by the National Cancer Institute (NCI)-Navy Medical Oncology Branch, only four variant cell lines (SCLC-v) grew as adherent monolayers [6].
  • Thirty-two patients with stage III or IV invasive thymoma (14 women and 18 men; median age, 40 years) were treated at the Padua Medical Oncology Department from 1977 to 1988 [7].
  • Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society [8].
  • It also compares the phase III studies of these agents with those of the two most popular infusional 5-FU-based regimens: de Gramont and German AIO (The Association of Medical Oncology (AIO) of the German Cancer Society) [9].
  • The European Society for Medical Oncology (ESMO) and its activities through the Central Eastern European Task Force [10].

Chemical compound and disease context of Medical Oncology


Biological context of Medical Oncology

  • In summary, 47 patients with documented HHT and a bleeding problem were referred to San Joaquin Hematology Oncology Medical Group over a 2-year period [14].

Associations of Medical Oncology with chemical compounds


Gene context of Medical Oncology

  • This study examines for the first time the serum concentrations of circulating VCAM-1 and E-selectin in a consecutive series of 110 cancer patients seen in a general medical oncology clinic, and confirms and extends previous studies reporting measurement of circulating ICAM-1 [20].
  • Donald Metcalf's contributions to the understanding of haemopoietic growth factors have led to the use of G-CSF and GM-CSF as valuable new therapies in medical oncology [21].
  • Nasopharyngeal carcinoma: a medical oncology viewpoint. The Gustave Roussy experience [22].
  • In total, 130 patients were treated at two medical oncology institutions with TOM (3 mg/m2) (52 patients) or TOM plus oxaliplatin (TOMOX) (100 mg/m2 day 1 or 70 mg/m2 day 1, 8) (78 patients) [23].
  • Sixteen patients of 104 treated for NSGCT at the CRC Wessex Medical Oncology Unit (Southampton, UK) presented with serum HCG greater than 25,000 [24].

Analytical, diagnostic and therapeutic context of Medical Oncology


  1. Sequential methotrexate and 5-fluorouracil (FU) vs. FU alone in metastatic colorectal cancer. Results of a randomized multicenter trial. The Association of Medical Oncology (AIO) of the German Cancer Society. Herrmann, R., Knuth, A., Kleeberg, U., Middeke, H., Korsten, F.W., Trux, F.A., Schmieder, A., Evers, C. Ann. Oncol. (1992) [Pubmed]
  2. FEP regimen (epidoxorubicin, etoposide and cisplatin) in advanced gastric cancer, with or without low-dose GM-CSF: an Italian Trial in Medical Oncology (ITMO) study. Bajetta, E., Di Bartolomeo, M., Carnaghi, C., Buzzoni, R., Mariani, L., Gebbia, V., Comella, G., Pinotti, G., Ianniello, G., Schieppati, G., Bochicchio, A.M., Maiorino, L. Br. J. Cancer (1998) [Pubmed]
  3. Biological and clinical evaluation of lanreotide (BIM 23014), a somatostatin analogue, in the treatment of advanced breast cancer. A pilot study by the I.T.M.O. Group. Italian Trials in Medical Oncology. Di Leo, A., Ferrari, L., Bajetta, E., Bartoli, C., Vicario, G., Moglia, D., Miceli, R., Callegari, M., Bono, A. Breast Cancer Res. Treat. (1995) [Pubmed]
  4. Clinical efficacy of octreotide in the treatment of metastatic neuroendocrine tumors. A study by the Italian Trials in Medical Oncology Group. di Bartolomeo, M., Bajetta, E., Buzzoni, R., Mariani, L., Carnaghi, C., Somma, L., Zilembo, N., di Leo, A. Cancer (1996) [Pubmed]
  5. Modified ESHAP as salvage chemotherapy for recurrent or refractory non-Hodgkin's lymphoma: results of a single-center study of 32 patients. Modified etoposide, methylprednisolone, cytarabine and cisplatin. Oztürk, M.A., Barişta, I., Altundağ, M.K., Türker, A., Yalçin, S., Celik, I., Güllü, I., Güler, N., Ozişik, Y., Kars, A., Kansu, E., Baltali, E., Tekuzman, G. Chemotherapy. (2002) [Pubmed]
  6. An adherent subline of a unique small-cell lung cancer cell line downregulates antigens of the neural cell adhesion molecule. Doyle, L.A., Borges, M., Hussain, A., Elias, A., Tomiyasu, T. J. Clin. Invest. (1990) [Pubmed]
  7. Chemotherapy of invasive thymoma. Fornasiero, A., Daniele, O., Ghiotto, C., Sartori, F., Rea, F., Piazza, M., Fiore-Donati, L., Morandi, P., Aversa, S.M., Paccagnella, A. J. Clin. Oncol. (1990) [Pubmed]
  8. Phase I trial of methotrexate-albumin in a weekly intravenous bolus regimen in cancer patients. Phase I Study Group of the Association for Medical Oncology of the German Cancer Society. Hartung, G., Stehle, G., Sinn, H., Wunder, A., Schrenk, H.H., Heeger, S., Kränzle, M., Edler, L., Frei, E., Fiebig, H.H., Heene, D.L., Maier-Borst, W., Queisser, W. Clin. Cancer Res. (1999) [Pubmed]
  9. Which endpoints should we use in evaluating the use of novel fluoropyrimidine regimens in colorectal cancer? Twelves, C.J., Cassidy, J. Br. J. Cancer (2002) [Pubmed]
  10. The European Society for Medical Oncology (ESMO) and its activities through the Central Eastern European Task Force. Hansen, H.H., Bjerre-Jepsen, M., Hossfeld, D. Ann. Oncol. (1999) [Pubmed]
  11. Aminoglutethimide and medroxyprogesterone acetate in the treatment of patients with advanced breast cancer. A phase II study of the Association of Medical Oncology of the German Cancer Society (AIO). Wander, H.E., Nagel, G.A., Blossey, H.C., Kleeberg, U. Cancer (1986) [Pubmed]
  12. Use of clonidine to treat hot flashes secondary to leuprolide or goserelin. Bressler, L.R., Murphy, C.M., Shevrin, D.H., Warren, R.F. The Annals of pharmacotherapy. (1993) [Pubmed]
  13. Pirarubicin in advanced non-small cell lung cancer. A trial of the Phase I/II Study Group of the Association for Medical Oncology of the German Cancer Society. Drings, P., Günther, I.U., Gatzemeier, U., Berdel, W., Stahl, M., Salewski, E., Edler, L. Onkologie. (1990) [Pubmed]
  14. Hereditary hemorrhagic telangiectasia and disseminated intravascular coagulation: a new clinical syndrome. Bick, R.L. Ann. N. Y. Acad. Sci. (1981) [Pubmed]
  15. Etoposide, doxorubicin and cisplatin (EAP) treatment in advanced gastric carcinoma: a multicentre study of the Italian Trials in Medical Oncology (I.T.M.O.) Group. Bajetta, E., Di Bartolomeo, M., de Braud, F., Bozzetti, F., Bochicchio, A.M., Comella, P., Fagnani, D., Farina, G., Ferroni, C., Franchi, R. Eur. J. Cancer (1994) [Pubmed]
  16. Oxaliplatin: a review of preclinical and clinical studies. Raymond, E., Chaney, S.G., Taamma, A., Cvitkovic, E. Ann. Oncol. (1998) [Pubmed]
  17. A phase II trial of dacarbazine, fluorouracil and epirubicin in patients with neuroendocrine tumours. A study by the Italian Trials in Medical Oncology (I.T.M.O.) Group. Di Bartolomeo, M., Bajetta, E., Bochicchio, A.M., Carnaghi, C., Somma, L., Mazzaferro, V., Visini, M., Gebbia, V., Tumolo, S., Ballatore, P. Ann. Oncol. (1995) [Pubmed]
  18. Melanoma: therapeutic options with recombinant interferons. Kirkwood, J.M., Ernstoff, M. Semin. Oncol. (1985) [Pubmed]
  19. A pharmacokinetic study of high-dose metoclopramide suppositories. Hardy, F., Warrington, P.S., MacPherson, J.S., Hudson, S.A., Jefferson, G.C., Smyth, J.F. Journal of clinical pharmacy and therapeutics. (1990) [Pubmed]
  20. Circulating intercellular adhesion molecule-1 (ICAM-1), E-selectin and vascular cell adhesion molecule-1 (VCAM-1) in human malignancies. Banks, R.E., Gearing, A.J., Hemingway, I.K., Norfolk, D.R., Perren, T.J., Selby, P.J. Br. J. Cancer (1993) [Pubmed]
  21. Forty years at the pitface in the Walter and Eliza Hall Institute of Medical Research. Metcalf, D. Med. J. Aust. (1996) [Pubmed]
  22. Nasopharyngeal carcinoma: a medical oncology viewpoint. The Gustave Roussy experience. Gasmi, J., Bachouchi, M., Cvitkovic, E., Boussen, H., Azli, N., Rahal, M., Domenge, C., Wibault, P., Eschwege, F., Schwaab, G. Ann. Oncol. (1990) [Pubmed]
  23. Raltitrexed-induced hepatotoxicity: multivariate analysis of predictive factors. Massacesi, C., Santini, D., Rocchi, M.B., La Cesa, A., Marcucci, F., Vincenzi, B., Delprete, S., Tonini, G., Bonsignori, M. Anticancer Drugs (2003) [Pubmed]
  24. Nonseminomatous germ cell tumor with very high serum human chorionic gonadotropin. McKendrick, J.J., Theaker, J., Mead, G.M. Cancer (1991) [Pubmed]
  25. Problems encountered in an intensive care medical oncology unit in Paris. Adonis, C. Prog. Clin. Biol. Res. (1983) [Pubmed]
  26. Consensus conference on palliative treatment of stage IV non-small cell lung cancer. Consensus meeting of the Netherlands Society for Medical Oncology and the Taskforce on Lung Cancer of the Dutch Society of Physicians for Lung Diseases and Tuberculosis. Tjan-Heijnen, V.C., Groen, H.J., Schramel, F.M., Stoter, G. The Netherlands journal of medicine. (2001) [Pubmed]
WikiGenes - Universities